Dateline City:
WHITEHOUSE STATION, N.J.
ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced that
the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY
(vorapaxar) for the reduction of thrombotic cardiovascular events in
patients with a history of heart attack (myocardial infarction) or in
patients with narrowing of leg arteries, called peripheral arterial
disease (PAD).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more